Staar Surgical Co. Stock
Staar Surgical Co. Stock
The Staar Surgical Co. stock is trending slightly upwards today, with an increase of €0.41 (0.970%) compared to yesterday's price.
With 11 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
With a target price of 49 € there is a slightly positive potential of 14.78% for Staar Surgical Co. compared to the current price of 42.69 €.
Pros and Cons of Staar Surgical Co. in the next few years
Pros
?
S********** s********
?
M***** P*******
?
B****
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Staar Surgical Co. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Staar Surgical Co. | 0.970% | -3.460% | -4.986% | -30.108% | 47.055% | -61.120% | - |
| Orasure Tech | -0.980% | 2.642% | -8.182% | -18.548% | -32.215% | -32.306% | -41.827% |
| scPharmaceuticals | -3.170% | 0.943% | -6.550% | -58.039% | -25.565% | -11.203% | - |
| SI-BONE Inc | -3.700% | -2.985% | -7.143% | -39.815% | -31.579% | -51.128% | - |
Comments
STAAR Surgical (NASDAQ: STAA) had its price target raised by analysts at Mizuho from $45.00 to $53.00. They now have a "buy" rating on the stock.
Show more
Ratings data for STAA provided by MarketBeat
STAAR Surgical (NASDAQ: STAA) was upgraded by analysts at William Blair from a "market perform" rating to an "outperform" rating.
Show more
Ratings data for STAA provided by MarketBeat
STAAR Surgical (NASDAQ: STAA) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $50.00 price target on the stock.
Show more
Ratings data for STAA provided by MarketBeat
News
STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today
STAAR Surgical to Report First Quarter Results on May 7, 2024
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today
STAAR Surgical Announces Preliminary Net Sales for First Quarter 2024
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today